NovaBridge Biosciences (formerly I-Mab) has transitioned to a 'Global Biotechnology Platform 3.0' model, focusing on bridging Asian innovation to global markets. The company maintains a strong cash position of $228.3 million with a runway extending into Q4 2028, while advancing a clinical-stage pipeline led by the CLDN18.2 x 4-1BB bispecific antibody, givastomig.